BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fougera (AAA) First-To-Market With Metronidazole Topical Gel USP 0.75% (Rx)


6/6/2006 12:34:54 PM

MELVILLE, N.Y., June 6 /PRNewswire/ -- Specialty pharmaceutical manufacturer Fougera, a division of ALTANA Inc, today announced it is first- to-market with generic Metronidazole Topical Gel USP 0.75% (Rx). The patent on the branded product by Galderma, which generates approximately $75 million in sales annually, expires today.

(Photo: http://www.newscom.com/cgi-bin/prnh/20060606/NYTU002 )

With Metronidazole Topical Gel, Fougera becomes the first company to offer a complete range of generic Metronidazole products in all three presentations, including Cream, Lotion and now, Gel. All Fougera Metronidazole products are offered at the established strength of 0.75%, facilitating an easy transition to the more cost-effective generic product for existing patients, and providing an attractive option for new patients.

Metronidazole Topical Gel USP 0.75% (Rx) is indicated for the treatment of rosacea (see product package insert for full prescribing information). The Fougera gel product is available in 45g tubes (NDC # 0168-0275-45).

The approval of Metronidazole Topical Gel USP 0.75% (Rx) continues Fougera's record of achieving more topical FDA approvals than any other generic pharmaceuticals company in the past six years. This continuing stream of new products benefits both health care providers and patients seeking multi-source alternatives and reduced costs.

David Klaum, Senior Vice President, Commercial Business Operations, stated, "First-to-market Metronidazole Gel, an important addition to Fougera's line of facial products, joins our Metronidazole Cream and Metronidazole Lotion to give health care providers the ability to choose the topical formulation that's right for their patients. At Fougera, our focus is always on providing our customers with the quality generic products they demand, in the formulations that suit their individual needs."

Fougera is a specialty pharmaceutical manufacturer of topical steroids, antibiotics and antifungal products, as well as ophthalmics. For more information on Fougera's complete line of topicals, or any other quality Fougera product, please call Fougera Customer Service at (800) 645-9833. Or visit the company online at http://www.fougera.com.

Fougera is a leading manufacturer and distributor of a wide range of multi-source topical and ophthalmic pharmaceuticals, in both prescription and over-the-counter dosage forms.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060606/NYTU002PRN Photo Desk, photodesk@prnewswire.comFougera

CONTACT: Julie Gross Gelfand of HLD\Blankman Public Relations,+1-516-536-6822, +1-212-896-3926, or jgelfand@hldbnow.com, for Fougera



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES